News Releases

Baker Botts Client PetIQ to Acquire Capstar from Elanco Animal Health As Part of U.S. FTC Approval of Elanco-Bayer Deal

Release

WASHINGTON D.C., July 15, 2020 – Baker Botts L.L.P., a leading international law firm, announced today that its client PetIQ, Inc. (Nasdaq: PETQ), a leading pet medication and wellness company, will acquire Capstar®, an oral tablet that kills fleas in dogs and cats, from Elanco Animal Health Incorporated (NYSE: ELAN) in an all-cash $95 million deal following U.S. Federal Trade Commission approval of Elanco’s global acquisition of Bayer Animal Health.

 

The Baker Botts team was led by Antitrust Group Co-Chair Steve Weissman, assisted by Jana Seidl. Both are residents in the firm’s Washington D.C. office. Mr. Weissman previously served as Deputy Director for the FTC’s Bureau of Competition (2013-2015).

 

ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm of approximately 750 lawyers practicing throughout a network of 14 offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the energy and technology sectors. Since 1840, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.

Related Professionals